The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
 
Pascal Hammel
Honoraria - Celgene
Consulting or Advisory Role - Amgen; Celgene; ERYTECH Pharma (Inst); Halozyme; Shire; VECT-HORUS
Speakers' Bureau - Celgene; Shire
Travel, Accommodations, Expenses - Halozyme; Ipsen; Lilly; Merck Serono; Shire
 
Rossana Berardi
No Relationships to Disclose
 
Eric Van Cutsem
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Jaime Feliu
No Relationships to Disclose
 
Richard Greil
No Relationships to Disclose
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; Lilly; Merck KGaA; Servier; Sirtex Medical
Speakers' Bureau - Celgene; Merck KGaA; Sirtex Medical
Research Funding - Merck KGaA (Inst); Pfizer (Inst); Sirtex Medical (Inst)
 
Jean-Philippe Metges
No Relationships to Disclose
 
Peter Nygren
No Relationships to Disclose
 
Pia J. Osterlund
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck Serono; Roche; Sanofi; Servier/Shire
Speakers' Bureau - Prime Oncology
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst); Servier (Inst)
 
Vibeke Parner
No Relationships to Disclose
 
Thomas Seufferlein
No Relationships to Disclose
 
Anu Gupta
Employment - Erytech Pharma; Synta; Vertex
 
Sophie Salesse
Employment - Erytech Pharma
Stock and Other Ownership Interests - Erytech Pharma
Travel, Accommodations, Expenses - Erytech Pharma
 
Nigel Biswasbaldwin
Employment - Erytech Pharma
Stock and Other Ownership Interests - Erytech Pharma
Travel, Accommodations, Expenses - Erytech Pharma
 
Ayman Ibrahim
Employment - Erytech Pharma
Stock and Other Ownership Interests - Erytech Pharma
Travel, Accommodations, Expenses - Erytech Pharma
 
Hagop Youssoufian
Employment - Erytech Pharma
Travel, Accommodations, Expenses - Erytech Pharma
 
Iman El-Hariry
Employment - Erytech Pharma
Leadership - Erytech Pharma
Stock and Other Ownership Interests - Erytech Pharma
Travel, Accommodations, Expenses - Erytech Pharma
 
Manuel Hidalgo
Stock and Other Ownership Interests - Champions Oncology
Honoraria - Celgene; MSD Oncology; Novartis; Pfizer
Consulting or Advisory Role - Celgene; Lilly/ImClone; Merck; Novartis; Pfizer
Research Funding - Celgene; Merck Serono; Pfizer
Travel, Accommodations, Expenses - Celgene; Merck; Pfizer